Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTS2190 in Advanced Solid Tumors
NCT06224387Phase 2Recruiting
- Sponsor
- CytosinLab Therapeutics
- Start
- Jun 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CTS2190 in solid tumor, pancreatic cancer (PC), non-small cell lung cancer (NSCLC) and 3 more, sponsored by CytosinLab Therapeutics. Primary endpoints: Maximum Tolerated Dose at 25 days, Recommended Phase 2 Dose at 25 days and 1 more. Started Jun 2023; status: recruiting.
02
Drugs
CTS2190
03
Conditions
solid tumorpancreatic cancer (PC)non-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT06224387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06224387.